The trust fund for the program, which supports roughly 68 million Americans, is on schedule to be depleted in the next six years. Benefits could be cut on average by 22 percent. By Tara Siegel Bernard ...
Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer. Treatment with Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) ...
June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results